Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Visualizing drug effects over time in live animals using optical pharmacodynamics

A Publisher Correction to this article was published on 26 February 2025

This article has been updated

Measuring pharmacodynamics is crucial for drug development, but traditional pharmacodynamic studies based on tissue dissection and subsequent biochemical analysis are labor- and resource-intensive. We developed a non-invasive imaging method to efficiently and rapidly visualize the pharmacodynamics of kinase inhibitors and degraders using an engineered kinase-modulated bioluminescent indicator.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: KiMBI enables non-invasive visualization of AKT inhibitor and degrader pharmacodynamics in live mice.

Change history

References

  1. Abdel-Rahman, S. M. & Kauffman, R. E. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu. Rev. Pharmacol. Toxicol. 44, 111–136 (2004). A review that presents the concept and importance of pharmacodynamics.

    Article  CAS  PubMed  Google Scholar 

  2. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988–1004 (2005). A review that presents the importance of AKT as a drug target.

    Article  CAS  PubMed  Google Scholar 

  3. Wu, Y. et al. Kinase-modulated bioluminescent indicators enable noninvasive imaging of drug activity in the brain. ACS Cent. Sci. 9, 719–732 (2023). This paper reports a KiMBI developed for ERK.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mullard, A. FDA approves first-in-class AKT inhibitor. Nat. Rev. Drug Discov. 23, 9 (2024). This news-in-brief article presents the approval of capivasertib by the FDA.

    Article  CAS  PubMed  Google Scholar 

  5. Ou, Z. et al. Achieving optical transparency in live animals with absorbing molecules. Science 385, eadm6869 (2024). This article reports a technique that makes the skin of a live mouse transparent.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Wu, Y. et al. Pharmacodynamics of Akt drugs revealed by a kinase-modulated bioluminescent indicator. Nat. Chem. Biol. https://doi.org/10.1038/s41589-025-01846-y (2025).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Visualizing drug effects over time in live animals using optical pharmacodynamics. Nat Chem Biol 21, 1136–1137 (2025). https://doi.org/10.1038/s41589-025-01847-x

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41589-025-01847-x

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research